替沙来仑赛治疗复发难治弥漫大B细胞淋巴瘤患者长期生活质量报告
JULIET 2期试验评估单次替沙来仑赛输注治疗成人复发难治弥漫大B细胞淋巴瘤,中位随访19.3个月。99例可评估患者总缓解率54%,完全缓解率40%。缓解患者在FACT-Lym所有评分及SF-36 8个维度中5个显示持续且有临床意义的改善。
要点
- 替沙来仑赛缓解患者长期HRQoL持续改善
- FACT-Lym所有评分在所有时间点均改善
- SF-36 8个维度中5个改善超过最小临床重要差异
核心结论
- JULIET 2期试验长期随访显示,复发难治弥漫大B细胞淋巴瘤患者对替沙来仑赛治疗有应答者,健康相关生活质量获得持续且有临床意义的改善。
研究设计与样本
- JULIET 2期试验纳入≥18岁、≥2线治疗后复发难治弥漫大B细胞淋巴瘤且自体干细胞移植失败或不适合移植的患者,单次输注替沙来仑赛。
- 采用FACT-Lym和SF-36量表在基线及第3、6、12、18个月评估健康相关生活质量,中位随访19.3个月。
主要发现
- 截至2018年5月21日,115例患者接受替沙来仑赛输注,99例可评估,总缓解率54%,完全缓解率40%。
- 108例完成基线HRQoL评估,其中57例最终达到完全缓解或部分缓解;应答者中30例和21例分别完成第12个月和第18个月评估。
- 达到完全缓解或部分缓解的患者在所有时间点FACT-Lym所有评分均持续改善,SF-36 8个维度中5个改善超过最小临床重要差异。
临床怎么用
- 对于复发难治弥漫大B细胞淋巴瘤适合替沙来仑赛治疗的患者,可预期应答者获得长期生活质量改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were used to measure HRQoL at baseline and months 3, 6, 12, and 18. At data cutoff (21 May 2018), 115 patients had received tisagenlecleucel infusion. Among the 99 patients evaluated, overall response rate was 54%, and 40% of patients achieved complete response (CR). Initially, 108 patients completed the HRQoL assessments at baseline, including 57 patients who eventually achieved CR or partial response (PR). Further, 30 and 21 patients in clinical response who completed assessments at baseline also completed assessments at months 12 and 18, respectively. Patients who achieved CR or PR sustained HRQoL improvement in all FACT scores at all time points. SF-36 instruments showed improvement above the minimal clinically important differences on 5 of 8 subscales. Long-term follow-up in the phase 2 JULIET study demonstrated that patients with r/r DLBCL who respond to tisagenlecleucel therapy had sustained, clinically meaningful improvements in HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT02445248.
引用
- Maziarz RT, Waller EK, Jaeger U, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32074277. doi:10.1182/bloodadvances.2019001026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。